Quantitative Modeling & Simulation Case Studies
Mechanism-Based PK/PD for Direct Phase III Without Phase II
Proton pump inhibitors have well-defined pharmacological mechanisms. Intragastric pH as PD biomarker correlates closely with clinical endpoints. Mechanism-driven PK/PD models are applied to screen optimal clinical regimens and support Phase II waiver application, enabling direct transition to Phase III trials without intermediate Phase II clinical studies, shortening global drug development timelines.
